The procedure was performed Nov. 30 at the Lexington (Ky.) Surgery Center, the report said. It is used to treat wet age-related macular degeneration, the leading cause of blindness in people over the age of 60.
The treatment, Genentech’s Susvimo, was approved by the FDA in October, the report said. It is surgically implanted in the eye via injection and slowly releases vascular endothelial growth factor, which combats the eye disease. Patients receive two refill injections per year, as opposed to the previously available treatment’s monthly injections of the growth factor.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
